Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

User asks if mixing RU58841 solution with Serioxyl is okay for better scalp coverage and worries about reduced effects.

Crushing finasteride pills into stemoxydine may not be effective without removing the coating first. It's unclear if the pills dissolve completely or settle as sediment.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.